scholarly journals THE UNFORTUNATE EVENT: AN ACUTE MASSIVE PULMONARY EMBOLISM FOLLOWING A MYOCARDIAL INFARCTION

Respirology ◽  
2019 ◽  
Vol 24 (S2) ◽  
pp. 101-102
Keyword(s):  
Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Massive Pulmonary Embolism

Could advanced drug delivery systems be the future in cardiovascular revascularization medicine?

Vascular ◽  
2016 ◽  
Vol 25 (4) ◽  
pp. 447-448 ◽  
Author(s):  
Marco Zuin ◽  
Gianluca Rigatelli ◽  
Giuseppe Faggian ◽  
Roberto L’Erario ◽  
Mauro Chinaglia ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Clinical Practice ◽  
Percutaneous Transluminal Coronary Angioplasty ◽  
Massive Pulmonary Embolism ◽  
Bleeding Events ◽  
Systemic Thrombolysis ◽  
Future Clinical Practice ◽  
Transluminal Coronary Angioplasty

Acute myocardial infarction, stroke and pulmonary embolism required a prompt revascularization to restore the normal blood flow as soon as possible. Fibrinolytic treatment has gradually become both dated and underused in the treatment of acute myocardial infarction, after the wide diffusion of cathlab and percutaneous transluminal coronary angioplasty. Conversely, the use of systemic thrombolysis remained a benchmark in the treatment of both ischemic stroke and massive pulmonary embolism. In daily clinical practice, the use of thrombolytic agents is often limited by absolute and/or relative contraindications and possible adverse events after the drug administration, as intracranial and/or extracranial bleeding events. To minimize these problems, during the last years, the introduction of nanotechnology in the field of cardiovascular revascularization medicine has created several fascinating results. In the present article, we describe these recent findings and their possible implications in future clinical practice.

scholarly journals Massive pulmonary embolism presenting with hemoptysis and S1Q3T3 ECG findings

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mehmet Sami Islamoglu ◽  
Mehmet Dokur ◽  
Emrah Ozdemir ◽  
Omer Faruk Unal
Keyword(s):  
Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Main Pulmonary Artery ◽  
Blood Gas Analysis ◽  
Massive Pulmonary Embolism ◽  
Gas Analysis ◽  
Case Presentation ◽  
St Segment Elevation ◽  
Pulmonary Angiogram ◽  
Electrocardiographic Findings

Abstract Background Venous thromboembolism clinically presenting with a deep vein thrombosis or pulmonary embolism is among the most commonly seen cardiovascular syndromes. The aim of this case presentation is to emphasise the typical electrocardiographic findings that are detected with massive pulmonary embolism along with the electrocardiographic S1Q3 and S1Q3T3 accompanied by T negativity at the D3 derivation based on prevalent T negativity. Case presentation We present the case of an adult male who presented with a massive pulmonary embolism that was associated with tachycardia, haemoptysis and typical S1Q3T3 electrocardiographic findings. Tomographic findings showed filling defects in the two main pulmonary artery lumens, which were found to be compatible with a massive embolism. Intravenous heparin was injected (5000 IU), and low molecule weight heparin (LMWH) treatment was initiated. After two days of observation and treatment in the coronary intensive care unit, the patient was discharged for outpatient care. Discussion Massive pulmonary embolism is an urgent life-threatening clinical situation that is frequently confused with acute ST elevation myocardial infarction. The definitive diagnosis of massive pulmonary embolism was made with a computed tomography pulmonary angiogram. Electrocardiographic findings and hypoxic hypercarbia in the blood gas analysis are typical. Early diagnosis with laboratory and imaging investigations is vital in the treatment and prognosis of pulmonary embolism. Conclusions Ventricular overload signs accompanied by ST segment elevation in electrocardiography and S1Q3 and prevalent T negativity are crucial features in terms of distinguishing between pulmonary embolism and myocardial infarction and selecting effective treatments for patients admitted to the emergency department.

It's a ST-Elevation Myocardial Infarction (STEMI), or Is It? Massive Pulmonary Embolism Presenting as STEMI

2018 ◽  
Vol 55 (1) ◽  
pp. 125-127 ◽  
Author(s):  
Osama Dasa ◽  
Mohammed Ruzieh ◽  
Zaid Ammari ◽  
Mubbasher A. Syed ◽  
Kris R. Brickman ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Massive Pulmonary Embolism ◽  
St Elevation Myocardial Infarction ◽  
St Elevation

Use of Thrombolytics

2018 ◽  
pp. 139-149
Author(s):  
Albert. A. Scappaticci ◽  
Ronak Patel ◽  
Sun Ho Ahn
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Ischemic Stroke ◽  
Massive Pulmonary Embolism ◽  
Pleural Space ◽  
Technical Aspects ◽  
Thrombolytic Agents ◽  
History Of ◽  
Indications For Use

This chapter recounts the history of thrombolytic agents, those agents currently available, and indications for use. Clinical agents have expanded over the 80 years since they were discovered, primarily in the pleural space. Thrombolytic agents can be administered systemically (i.e., intravenously) to treat ischemic stroke, massive pulmonary embolism (PE), and acute myocardial infarction. They also can be delivered directly to the site of a thrombus via catheter, also known as catheter-directed therapy (CDT). To perform CDT safely and effectively, an understanding of the pharmacology and technical aspects of delivering agents is critical. This chapter will review in detail the indications for use, contraindications to CDT, technical aspects, and specific recommendations for monitoring during use.

Sign in / Sign up

Export Citation Format

Share Document